How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,228 results for

Mean Corpuscular Volume

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. MKSAP: 55-year-old woman after bariatric surgery

ago, was normal. On physical examination, blood pressure is 140/79 mm Hg and pulse rate is 63/min. BMI is 25. The examination is otherwise unremarkable. Laboratory studies reveal a hemoglobin level of 10.5 g/dL (105 g/L) and a mean corpuscular volume of 95 fL. Which of the following deficiencies best explains this patient’s current findings? A. Copper B. Iron C. Vitamin A D. Vitamin B12 MKSAP Answer and Critique The correct answer is C. Vitamin A. Vitamin A deficiency is most likely to explain (...) (vitamin B6). Copper deficiency may cause muscle weakness due to myeloneuropathy, ataxia, and cognitive deficits that may be difficult to differentiate from B12 deficiency. Less common neurologic findings include bilateral visual loss. Hematologic findings in copper deficiency include microcytic anemia, which may mimic iron deficiency anemia, and leukopenia. Although iron deficiency does occur following RYGB, this patient is on iron replacement and has a normal mean corpuscular volume. Patients

2018 KevinMD blog

102. Oral Iron Absorption Study

of erythropoiesis. Change from Baseline in hematocrit at Days 14 and 28 [ Time Frame: Baseline (Day 1), Days 14 and 28 ] Blood samples will be collected to characterize the effect of daprodustat or rhEPO on indices of erythropoiesis. Change from Baseline in red blood cell number at Days 14 and 28 [ Time Frame: Baseline (Day 1), Days 14 and 28 ] Blood samples will be collected to characterize the effect of daprodustat or rhEPO on indices of erythropoiesis. Change from Baseline in mean corpuscular volume at Days (...) of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03457701 Recruitment Status : Not yet recruiting First Posted : March 7, 2018 Last Update Posted : March 18, 2019 See Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief

2018 Clinical Trials

103. GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

assessment for clinical chemistry parameters will include blood urea nitrogen (BUN), creatinine, glucose, potassium, sodium, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, total and direct bilirubin, total protein and albumin. Number of subjects with abnormal clinical hematology parameters [ Time Frame: Up to 58 days ] Laboratory assessment for clinical hematology will include platelet, red blood cell (RBC), hemoglobin, hematocrit, mean corpuscular volume (...) (MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils Number of subjects with abnormal urinalysis parameters [ Time Frame: Up to 58 days ] Laboratory assessment for urinalysis will include specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite and leukocyte. AUC from time zero (pre-dose) to last time of quantifiable concentration (AUC[0-t]) of danirixin reference

2018 Clinical Trials

104. A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers

] ] Safety and tolerability of AZD5718 by assessment of urinalysis (glucose). Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Mean corpuscular volume (MCV) [ Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose] ] Safety and tolerability of AZD5718 by assessment of MCV. Safety and tolerability of AZD5718 by assessment (...) count [ Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose] ] Safety and tolerability of AZD5718 by assessment of reticulocytes absolute count. Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- mean corpuscular hemoglobin (MCH) [ Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1

2018 Clinical Trials

105. Forearm Blood Flow in Chronic Kidney Disease Subjects With Anemia (FBF-CKD)

(Day1) to Day 59 ] Blood samples will be collected to measure MCH. Absolute values of the hematology parameter of mean corpuscular volume (MCV) [ Time Frame: Up to 59 days ] Blood samples will be collected to measure MCV. Change from Baseline in hematology parameter of MCV [ Time Frame: Baseline (Day1) to Day 59 ] Blood samples will be collected to measure MCV. Absolute values of clinical laboratory parameters of sodium, potassium, carbon-dioxide (total), chloride, glucose and urea [ Time Frame: Up (...) values of hematology parameter of red blood cell distribution width (RDW) [ Time Frame: Up to 59 days ] Blood samples will be collected to measure RDW. Change from Baseline in RDW [ Time Frame: Baseline (Day1) to Day 59 ] Blood samples will be collected to measure RDW. Absolute values of the hematology parameter of mean corpuscular hemoglobin (MCH) [ Time Frame: Up to 59 days ] Blood samples will be collected to measure MCH. Change from Baseline in hematology parameter of MCH [ Time Frame: Baseline

2018 Clinical Trials

106. Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Up to 2 years ] The following clinical chemistry parameters will be evaluated: blood urea nitrogen (BUN), creatinine, glucose, calculated creatinine clearance (CrCl), potassium, sodium, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT (...) or more studies before adding more. Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03447314 Recruitment Status : Recruiting

2018 Clinical Trials

107. Vitamin D Supplementation in Children With Sickle Cell Disease

in neutrophil counts [ Time Frame: 3 months ] Group difference in the mean change of blood neutrophil counts from baseline to 3 months Mean change in mean corpuscular volume [ Time Frame: 3 months ] Group difference in the mean change of blood mean corpuscular volume from baseline to 3 months Mean change in serum creatinine [ Time Frame: 3 months ] Group difference in the mean change of serum creatinine from baseline to 3 months. Mean change in serum bilirubin [ Time Frame: 3 months ] Group difference (...) in Children With Sickle Cell Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03417947 Recruitment Status : Not yet recruiting First Posted : January 31, 2018 Last Update Posted : September 14, 2018 See Sponsor: St

2018 Clinical Trials

108. Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

related reactions will be summarized. Number of subjects with abnormal hematology parameters [ Time Frame: Up to Day 28 ] The following hematology parameters will be assessed: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), percentage of reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Up to Day 28 (...) of 89Zirconium-labelled GSK2398852 Using PET Imaging The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03417830 Recruitment Status : Terminated (Change in benefit/risk profile.) First Posted : January 31, 2018 Last Update Posted : December 12, 2018 Sponsor: GlaxoSmithKline Information provided by (Responsible

2018 Clinical Trials

109. Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Extension & Dissemination

Lipids at 3, 6, and 12 months [ Time Frame: Baseline, 3 months, 6 months, 12 months ] Total cholesterol, triglycerides, HDL, LDL (mmol/L) Change from Baseline Hemoglobin at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Hemoglobin (g/L) Change from Baseline Red Blood Cell Count at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Red blood cell count (10^12/L) Change from Baseline Mean Corpuscular Volume at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Mean (...) Corpuscular Volume (fL) Change from Baseline Mean Corpuscular Hemoglobin at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Mean Corpuscular Hemoglobin (pg) Change from Baseline Liver Functioning at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] ALT (U/L), AST (U/L), Alkaline phosphatase (U/L), r-GT (U/L) Change from Baseline Bilirubin at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Total bilirubin (µmol/L), Direct bilirubin (µmol/L) Change from Baseline Blood

2018 Clinical Trials

110. To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S (...) will be collected for PK analysis. Part 1: CL/F for 3TC 30 mg- following pediatric TRIUMEQ dispersible tablets-direct to mouth [ Time Frame: Pre-dose, 0.25 hour, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose before discharge at the end of each TP ] Whole blood samples of approximately 2 mL will be collected for PK analysis. Part 1: Apparent volume of distribution (Vz/F) for DTG 50 mg- following adult TRIUMEQ conventional tablet - direct to mouth [ Time Frame: Pre-dose, 0.25 hour, 0.5

2018 Clinical Trials

111. A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

; HDL = high-density lipoprotein; LDH = lactate dehydrogenase; LDL = low-density lipoprotein; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; RBC = red blood cell. Known allergy to tetracycline antibiotics or any of the excipients in TP 271 Clinically significant abnormality on a 12-lead ECG, which includes the following: Rhythm other than sinus Corrected QT interval using Fridericia's formula (QTcF) >450 msec Evidence of second (...) Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03450187 Recruitment Status : Recruiting First Posted : March 1, 2018 Last Update Posted : April 27, 2018 See Sponsor: Tetraphase Pharmaceuticals, Inc. Collaborator

2018 Clinical Trials

112. A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

, dosing sessions of Part A and Part B and follow-up (5 to 7 days after final dose) ] To assess HCT (RBC) and reticulocyte absolute count (immature RBCs) as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules (fast rate and Int. rate) and oral suspension (reference). Laboratory assessments: Hematology - Mean corpuscular volume (MCV) [ Time Frame: At screening, dosing sessions of Part A and Part B and follow-up (5 to 7 days after final dose (...) ) ] To assess MCV as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules (fast rate and Int. rate) and oral suspension (reference). Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: At screening, dosing sessions of Part A and Part B and follow-up (5 to 7 days after final dose) ] To assess MCH as a variable of safety and tolerability after administration of single oral dose of AZD9977 capsule, ER capsules (fast rate

2018 Clinical Trials

113. A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

parameters: Injection phase [ Time Frame: Up to 623 days ] Hematology parameters will be analyzed including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell (WBC) count, reticulocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, mean corpuscular hemoglobin concentration (MCHC), neutrophils lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal values for urinalysis: Injection phase [ Time (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2018 Clinical Trials

114. Full blood count values as a predictor of poor outcome of pneumonia among HIV-infected patients. (PubMed)

. We assessed the different values of the first blood count performed on the patient as follows; total white blood cells (WBC), neutrophils, lymphocytes (LYM), basophils, eosinophils (EOS), red blood cells (RBC), hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin, red blood cell distribution width (RDW), platelets (PLT), mean platelet volume, and platelet distribution width (PDW). The primary outcome measure was 30-day mortality (...) and the secondary, admission to an intensive care unit (ICU). The predictive power of the variables was determined by statistical calculation.One hundred sixty HIV-infected patients with pneumonia were identified. The mean age was 42 (11) years, 99 (62%) were male, 79 (49%) had ART. The main route of HIV transmission was through parenteral administration of drugs. Streptococcus pneumonia was the most frequently identified etiologic agent of CAP The univariate analysis showed that the values of PLT (p < 0.009

Full Text available with Trip Pro

2018 BMC Infectious Diseases

115. Exploring Adherence Monitoring in Sickle Cell Disease

adherence to mean corpuscular volume (MCV) lab values [ Time Frame: Continuous over two months, baseline to off study ] For each subject, we will calculate the proportion of days of opening the AdhereTech device across the two month study period (days with missing information will not be counted). We will extract mean corpuscular volume (MCV; L) lab value from each subject's medical record. We will estimate the Spearman's rank-based correlation, with 95% confidence interval, of the AdhereTech device (...) adherence with the mean corpuscular volume (MCV) lab value . Estimate the association between AdhereTech device HU adherence to the Medication Possession Ratio (MPR) [ Time Frame: Continuous over two months, baseline to off study ] For each subject, we will calculate the proportion of days of opening the AdhereTech device across the two month study period (days with missing information will not be counted). Medication Possession Ratio (MPR) will be calculated as: [(number of days medication in family's

2018 Clinical Trials

116. Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women

corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, erythrocyte distribution width, platelets, neutrophils, lymphocytes, monocytes, eosinophils. Blood chemistry 27 elements: glucose, urea, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, uric acid, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein cholesterol, non-HDL cholesterol, atherogenic index, total protein, albumin, globulins, albumin/globulin ratio (...) (100). Please remove one or more studies before adding more. Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03737656 Recruitment Status : Active, not recruiting First Posted : November 9

2018 Clinical Trials

117. Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients

baseline and end line of intervention The mean corpuscular volume (MCV) [ Time Frame: Through study completion, an average of 1 yea ] The MCV in fl at both baseline and end line of intervention The mean corpuscular hemoglobin (MCH) [ Time Frame: Through study completion, an average of 1 yea ] The MCH in pg at both baseline and end line of intervention The mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: Through study completion, an average of 1 yea ] The MCH in g/dl at both baseline (...) and end line of intervention The Platelet count [ Time Frame: Through study completion, an average of 1 yea ] The Platelet count as cells/ ul at both baseline and end line of intervention The of Hemoglobin [ Time Frame: Through study completion, an average of 1 yea ] The Hemoglobin in g/dl at both baseline and end line of intervention The mean platelet volume (MPV) [ Time Frame: Through study completion, an average of 1 yea ] The MPV in fl at both baseline and end line of intervention The level

2018 Clinical Trials

118. Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate

corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, erythrocyte distribution width, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Blood chemistry 27 elements: glucose, urea, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, uric acid, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein (LDL), cholesterol, non-HDL cholesterol, atherogenic index, total protein, albumin, globulins, albumin (...) one or more studies before adding more. Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03749733 Recruitment Status

2018 Clinical Trials

119. Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

such as mean corpuscular hemoglobin will be evaluated. Change from Baseline of hematology parameter: mean corpuscular volume [ Time Frame: Baseline and up to 106 Weeks ] Change from Baseline for parameter such as mean corpuscular volume will be evaluated. Change from Baseline in hematology parameter: Red blood cell (RBC) count [ Time Frame: Baseline and up to 106 Weeks ] Change from Baseline for parameter such as RBC count will be evaluated. Change from Baseline of Clinical chemistry parameters: glucose (...) from Baseline of hematology parameters: hematocrit [ Time Frame: Baseline and up to 106 Weeks ] Change from Baseline for parameter such as hematocrit will be evaluated. Change from Baseline of hematology parameter: hemoglobin [ Time Frame: Baseline and up to 106 Weeks ] Change from Baseline for parameter such as hemoglobin will be evaluated. Change from Baseline of hematology parameter: mean corpuscular hemoglobin [ Time Frame: Baseline and up to 106 Weeks ] Change from Baseline for parameter

2018 Clinical Trials

120. Iron Deficiency is Prevalent among HIV-Infected Kenyan Adults and is Better Measured by Soluble Transferrin Receptor than Ferritin. (PubMed)

corpuscular volume [MCV]) in newly diagnosed, antiretroviral therapy-naive, HIV-infected (N = 138) and uninfected (N = 52) Kenyan adults enrolled in a study of the immune response to malaria. We compared markers between infected and uninfected groups with t test and Wilcoxon Rank-Sum, used Spearman correlation to determine the association between iron and inflammatory markers, and applied logistic regression to determine which markers best predicted anemia. HIV-infected individuals had lower hemoglobin (P (...) Iron Deficiency is Prevalent among HIV-Infected Kenyan Adults and is Better Measured by Soluble Transferrin Receptor than Ferritin. Iron deficiency (ID) and human immunodeficiency virus (HIV) infection frequently coexist. Little data exist on ID in HIV-infected individuals, partly because the iron marker ferritin is altered by inflammation common in HIV infection. We measured iron biomarkers (ferritin, soluble transferrin receptor [sTfR], hepcidin) and red cell indices (hemoglobin, mean

2018 American Journal of Tropical Medicine & Hygiene

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>